New hope for breast cancer brain metastases: targeted drug Trop-2 ADC under study

NCT ID NCT07251868

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a drug called sacituzumab govitecan (Trop-2 ADC) in 100 breast cancer patients whose cancer has spread to the brain. Researchers want to see if the drug can shrink brain tumors and delay disease progression, while also monitoring side effects. The study collects data from routine care across multiple hospitals, without assigning patients to different treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Sacituzumab govitecan (a Trop-2 antibody-drug conjugate)
What this could lead to
If successful, this could show that sacituzumab govitecan is an effective treatment option for breast cancer that has spread to the brain, potentially improving control of brain tumors.
What could go wrong
This is an early real-world study without a control group, so results may be less reliable. The drug may cause side effects, and not all patients may benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN METASTASES FROM BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beijing Cancer Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100142, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.